GlobalData’s Clinical Trials Database shows the US leads global puberty suppression research with 25% of trials, as the Pathways trial’s proposed minimum eligibility age of 11 years sparks debate. The threshold could standardise inclusion criteria across gender-affirming care studies, but may complicate recruitment and shape future clinical and regulatory guidance.
Puberty blocker research and prescribing structures continue to be a crucial point of clinical, regulatory, and public debate, particularly in paediatric endocrinology and gender-affirming care pathways. Puberty suppression, primarily through the use of gonadotropin-releasing hormone (GnRH) analogues, is designed to temporarily pause the physical progression of puberty, allowing additional time for assessment and decision-making in carefully selected clinical populations. While established in conditions such as central precocious puberty, its use in gender-related care has become a key area of ongoing clinical investigation and policy scrutiny.
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
According to GlobalData’s Clinical Trials Database, current research activity in this area remains limited but internationally distributed. The US accounts for approximately 25% of total activity, positioning it as the leading country in this dataset. The remaining trials are distributed across Europe and other regions, reflecting a relatively small but globally dispersed evidence base. This concentration highlights both the emerging nature of the field and the variability in regulatory and clinical approaches across different healthcare systems.
Recent attention has focused on the Pathways clinical trial, which is reported to be exploring structured treatment frameworks involving puberty suppression and associated clinical decision points in adolescents. A key point of discussion in current reporting is the proposal or evaluation of a minimum eligibility set at age 11 years within aspects of the trial design. This threshold is clinically significant, as it aligns closely with the typical onset of early pubertal development in many individuals, and therefore intersects directly with decisions around timing, reversibility, and developmental stage at treatment initiation.
If implemented, a threshold at 11 years of age could have meaningful implications for future clinical trial design and regulatory guidance. It may contribute to more standardised inclusion criteria across studies, potentially improving the comparability of outcomes and safety data. However, it could also introduce new challenges in recruitment, particularly for younger cohorts at earlier stages of pubertal development, and may influence how clinicians interpret eligibility in real-world settings outside of trial environments.
